Amy O'Donnell, MD, JD, BS

Evaluation of Treatment Failure in a Randomized, Open-Label Study of Paliperidone Palmitate Versus Oral Antipsychotics for Recent-Onset Schizophrenia or Schizophreniform Disorder

Background: Despite the availability of effective treatments, outcomes for patients with schizophrenia remain poor. Nonadherence is common early in the disease course, a time when the gre...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020

Evaluation of Major Treatment Failures in Patients With Recent-Onset Schizophrenia: A Post Hoc Analysis From the Disease Recovery Evaluation and Modification (DREaM) Study

BACKGROUND: Major treatment failures (MTF), such as psychiatric hospitalization and arrest/incarceration, are associated with substantial economic and societal burden, especially for pers...

Amy O'Donnell , MD, JD, BS;

Ibrahim Turkoz , PhD;

Brianne Brown , PsyD;

Pamela Baker , PharmD;

Larry Alphs , MD, PhD;

10/08/2020

Defining “Adequately Treated”: Characteristics of Patients With Schizophrenia Successfully Transitioned From Paliperidone Palmitate Once Monthly to Paliperidone Palmitate Once-Every-3-Months

Objective: To identify patient characteristics associated with successful transition to once-every-3-months paliperidone palmitate (PP3M).

Edward S. Kim , MD, FACP, MBA;

Amy O'Donnell , MD, JD, BS;

Sanjai Rao , MD;

Ibrahim Turkoz , PhD;